Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT-Guided Maintenance Therapy in Previously Untreated Marginal Zone Lymphoma
NCT07917650Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started May 2026; status: active, not recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07917650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917650.